CN Patent

CN100370981C — 毛萼乙素在制药中的应用

Assigned to Affiliated Ruijin Hospital Of Shanghai Second Medical University · Expires 2008-02-27 · 18y expired

What this patent protects

本发明涉及毛萼乙素在制备治疗急性白血病药物中的应用；和毛萼乙素在制备治疗伯基特淋巴瘤药物中的应用。毛萼乙素毒性较小，药理作用强，预示着很好的药用前景。毛萼乙素能够提高过氧化物(ROS)的水平，影响IκBα的磷酸化和降解，以及阻止NF-κB进核，从而抑制NF-κB信号通路。毛萼乙素还能够下调ERK1/2的磷酸化水平，抑制MAPK信号通路。

USPTO Abstract

本发明涉及毛萼乙素在制备治疗急性白血病药物中的应用；和毛萼乙素在制备治疗伯基特淋巴瘤药物中的应用。毛萼乙素毒性较小，药理作用强，预示着很好的药用前景。毛萼乙素能够提高过氧化物(ROS)的水平，影响IκBα的磷酸化和降解，以及阻止NF-κB进核，从而抑制NF-κB信号通路。毛萼乙素还能够下调ERK1/2的磷酸化水平，抑制MAPK信号通路。

Drugs covered by this patent

Patent Metadata

Patent number
CN100370981C
Jurisdiction
CN
Classification
—
Expires
2008-02-27
Drug substance claim
No
Drug product claim
No
Assignee
Affiliated Ruijin Hospital Of Shanghai Second Medical University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.